Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Operating Expenses history runs 6 years deep, the most recent figure standing at $43.8 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 15.81% year-over-year to $43.8 million in Q1 2026; TTM through Mar 2026 was $159.3 million, a 30.49% decrease from a year earlier, with the FY2025 full-year figure at $153.3 million, down 61.88% from the prior year.
• Operating Expenses improved to $43.8 million in Q1 2026 per AMLX's latest filing, from $36.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $210.8 million in Q1 2024 and bottomed at $36.0 million in Q3 2025.
• The 5-year median for Operating Expenses is $55.0 million (2022), against an average of $68.5 million.
• Across the five-year window, Operating Expenses soared 271.57% in 2022 and sank 82.06% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $66.5 million in 2022, then jumped by 60.23% to $106.5 million in 2023, then plunged by 62.46% to $40.0 million in 2024, then decreased by 8.46% to $36.6 million in 2025, then grew by 19.6% to $43.8 million in 2026.
• Per Business Quant, the three latest AMLX Operating Expenses figures stand at $43.8 million (Q1 2026), $36.6 million (Q4 2025), and $36.0 million (Q3 2025).